Company

GYRE THERAPEUTICS, INC. (GYRE)

Standardized SEC financial data for GYRE THERAPEUTICS, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001124105 · NASDAQ · Pharmaceutical Preparations.

Gross margin

95.3%

Operating margin

9.8%

Net margin

4.3%

Revenue growth (YoY)

10.2%

Return on equity

3.5%

ROIC

7.5%

Free cash flow

-$180K

Debt / equity

0.00×

Ratios for fiscal year 2025, standardized from SEC filings.

Income statement

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$20.9M	$7.3M	$102.3M	$113.5M	$105.8M	$116.6M
Cost of revenue	—	—	$4.8M	$4.6M	$3.9M	$5.4M
Gross profit	—	—	$97.5M	$108.8M

Balance sheet

USD	FY2021	FY2022	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$46.9M	—	$25.2M	$33.5M	$11.8M	$37.1M
Inventory	—	—	$6.1M	$4.3M	$6.3M	$10.2M
Total current assets	$51.5M	—	$49.7M	$57.2M	$64.8M

Cash flow

USD	FY2022	FY2022	FY2022	FY2023	FY2024	FY2025
Operating cash flow	—	—	$10.7M	$25.9M	-$3.6M	$1.0M
Capital expenditures	—	—	$5.0M	$8.5M	$2.3M	$1.2M
Free cash flow	—	—	$5.7M	$17.4M	-$6.0M

Get GYRE data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/GYRE/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/GYRE/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View GYRE filings on SEC EDGAR →